Shots: Sangamo has an option to access Brammer’s AAV manufacturing facility with 2000-L bioreactor scale used in development of gene therapies. Additionally, Sangamo has rights for Brammer’s viral vector manufacturing […]readmore
Tags : Brammer Bio
Shots: Thermo Fischer acquires Brammer Bio, in all stock transaction for $1.7B in cash with its viral vector manufacturing techniques in gene and cell therapies. The transaction is expected to […]readmore